Rankings
▼
Calendar
SUPN Q4 2018 Earnings — Supernus Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena
SUPN
Supernus Pharmaceuticals, Inc.
$3B
Q4 2018 Earnings
Healthcare
Drug Manufacturers - Specialty & Generic
Income Statement
Revenue
$116M
+31.1% YoY
Gross Profit
$112M
96.4% margin
Operating Income
$40M
34.4% margin
Net Income
$26M
22.3% margin
EPS (Diluted)
$0.48
QoQ Revenue Growth
+12.6%
Cash Flow
Operating Cash Flow
$33M
Free Cash Flow
$33M
Stock-Based Comp.
$3M
Balance Sheet
Total Assets
$978M
Total Liabilities
$525M
Stockholders' Equity
$453M
Cash & Equivalents
$192M
Year-over-Year Comparison
Metric
Current
Year Ago
Change
Revenue
$116M
$88M
+31.1%
Gross Profit
$112M
$84M
+32.6%
Operating Income
$40M
$34M
+16.0%
Net Income
$26M
$14M
+89.6%
← FY 2018
All Quarters
Q1 2019 →